Atamyo Cleared in UK to Test ATA-100 for Limb-Girdle MD Type R9

Atamyo Cleared in UK to Test ATA-100 for Limb-Girdle MD Type R9

313783

Atamyo Cleared in UK to Test ATA-100 for Limb-Girdle MD Type R9

Atamyo Therapeutics has been given the go-ahead to start clinical testing of ATA-100, the company’s investigational gene therapy for a specific form of limb-girdle muscular dystrophy (LGMD) called type R9 (LGMDR9). With approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA), Atamyo now plans to start dosing  patients with ATA-100 “in the first half of 2022,” Sophie Olivier, MD, Atamyo’s chief medical officer, said in a press release. “We are thrilled to obtain…

You must be logged in to read/download the full post.